Rigel Pharmaceuticals Inc (RIGL)
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
📈 **POSITIVE** • Medium confidence analysis (68%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (78%) **Content type:** Clinical